ALBPS — Biophytis SA Share News
0.000.00%
Last trade - 00:00Brief: Biophytis: U.S. Centers To Restart Recruitment For COVA Phase 2-3 Study
Brief: Biophytis End-June Net Loss Reduced To 13.2 Million Euros
Brief: Biophytis To Restate Previously Issued Financial Statements
Brief: Biophytis: Promising Full Results From Sara-Interest Phase 2B Trial Of Sarconeos (BIO101)
Brief: Biophytis Says DMC Recommends Continuation Of Phase 2/3 COVA Study Without Protocol Amendment
Brief: Biophytis: Favorable Recommendation From DMC Based On Safety Analysis Of Sarconeos
Brief: Biophytis Announces The Issue Of 4,950,000 New Shares In A Capital Increase Reserved For Negma And The Performance Of The Judgments Of March 16, 2021 And July 16, 2021
Biophytis jumps after study shows drug candidate improves walking speed
Brief: Biophytis Announces Top Line Results Of Sara-Interest Phase 2 Study
Brief: Biophytis SA - Judge In Charge Of Overseeing Judgements Execution Rendered On July 16, 2021 A Judgement In Proceedings Between Co & Negma Group Ltd
Brief: Biophytis Appoints Jean Mariani As Chief Medical Officer
Brief: Biophytis SA Says Results Of SARA-INT Phase 2 Trial With Sarconeos In Sarcopenia To Be Released By August
Brief: Biophytis: New Convertible Bond Financing For Up To EUR 32 Million With Atlas
Brief: Biophytis Receives EUR 980,000 DeepTech Funding
Brief: Biophytis Gives Update On Sarconeos Programs
Brief: Biophytis Flags False Report On Sarconeos COVID-19 Study In Brazil
Brief: Biophytis SA Says Made Aware Of False Report Regarding Status Of Cova Study
U.S. STOCKS ON THE MOVE-Ingersoll Rand, InMode, Signet Jewelers
Brief: Biophytis Updates On Its Phase 2-3 COVA Study On COVID-19